Marrink J, Oosterom R, Bonfrer H M, Schröder F H, Mensink H J
Department of Internal Medicine, University Hospital, Groningen, The Netherlands.
Eur J Cancer. 1993;29A(4):570-1. doi: 10.1016/s0959-8049(05)80153-4.
The serum concentration of the cell proliferation marker TPS (tissue polypeptide-specific antigen) was compared with the tumour marker PSA (prostate specific antigen). PSA was found elevated in 50% of the benign prostatic hypertrophy (BPH) patients, in 88% of the patients with active prostate cancer and in 40% of the patients who were in an inactive phase. For TPS these values were 6, 34 and 0%, respectively. The metastatic progression was biochemically mirrored by pronounced elevations of PSA and TPS. These data suggest that TPS might be a valuable adjunct in the diagnosis and follow-up of patients with prostate cancer, especially in differentiating benign from malignant deterioration of the disease.
将细胞增殖标志物TPS（组织多肽特异性抗原）的血清浓度与肿瘤标志物PSA（前列腺特异性抗原）进行了比较。发现50%的良性前列腺增生（BPH）患者、88%的前列腺癌活跃期患者和40%的非活跃期患者的PSA升高。而对于TPS，这些数值分别为6%、34%和0%。PSA和TPS的显著升高在生化方面反映了转移进展。这些数据表明，TPS可能是前列腺癌患者诊断和随访中的一种有价值的辅助手段，尤其是在区分疾病的良性与恶性恶化方面。
